Abstract:Background Lung cancer has the highest cancer-related mortality worldwide. Lung adenocarcinoma (LUAD) is the most common histological subtype of non-small cell lung cancer (NSCLC). Chromatin licensing and DNA replication factor 1 (CDT1), a key regulator of cell cycle control and replication in eukaryotic cells, has been implicated in various cancer-related processes. Given its significant role in cancer, the focus on CDT1 in this study is justified as it holds promise as a potential biomarker or therapeutic target for cancer treatment. However, its prognostic value in lung adenocarcinoma (LUAD) remains unclear. Methods Bioinformatics analysis was conducted using data obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases were utilized to predict biological processes and signaling pathways, respectively. The LinkedOmics database was employed to identify differentially expressed genes (DEGs) associated with CDT1. Nomograms and Kaplan-Meier plots were generated to assess the survival rates of patients with lung adenocarcinoma (LUAD). To determine the RNA and protein expression levels of CDT1 in LUAD and adjacent normal tissues, quantitative polymerase chain reaction (qPCR) and immunohistochemistry techniques were employed, respectively. Results CDT1 was upregulated in the vast majority of cancer tissues, based on pan-cancer analysis in TCGA and GEO datasets, as to lung cancer, the level of CDT1 expression was much higher in LUAD tissue than in healthy lung tissue. Our clinical data supported these findings. In our study, we used a specific cutoff value to dichotomize the patient samples into high and low CDT1 expression groups. The Kaplan–Meier survival curve revealed poor survival rates in CDT1 high expression group than the low expression group. To determine if CDT1 expression was an independent risk factor in LUAD patients, univariate and multivariate Cox regression analyses were performed. The result showed that CDT1 was a potential novel prognosis factor for LUAD patients, whose prognosis was poorer when CDT1 expression was higher. Based on functional enrichment analysis, highly expressed DEGs of CDT1-high patients were predicted to be involved in the cell cycle. According to our analysis of immune infiltration, CDT1 exhibited a strong correlation with specific immune cell subsets and was found to be a significant predictor of poor survival in patients with LUAD. Conclusions Our research found that CDT1 was upregulated in LUAD and that high CDT1 expression predicted poor prognosis. We comprehensively and systematically analyzed the expression level in the datasets as well as in our own clinical samples, we also evaluated the prognostic and diagnostic value of CDT1, and finally, the potential mechanisms of CDT1 in the progression of LUAD. These results suggested that CDT1 may be a prognostic marker and therapeutic target for LUAD.

Clinical value of serum DJ-1 in lung adenocarcinoma

Dj-1 As A Potential Biomarker for the Early Diagnosis in Lung Cancer Patients

[Diagnosis Value of Serum NKX2-1 for Primary Lung Cancer].

Serum Dj-1 As A Diagnostic Marker and Prognostic Factor for Pancreatic Cancer

Interactive Verification Analysis of Multiple Sequencing Data for Identifying Potential Biomarker of Lung Adenocarcinoma

[DJ-1 Expression in Laryngeal Squamous Cell Carcinoma and Its Relationship with Tumor Recurrence and Metastasis].

Overexpression of DJ-1 Correlates with Aggressive Clinicopathological Characteristics and Poor Prognosis in Malignant Tumors: a Meta-Analysis

DJ-1, a novel biomarker and a selected target gene for overcoming chemoresistance in pancreatic cancer

DJ‑1 is a New Prognostic Marker and Predicts Chemotherapy Efficacy in Colorectal Cancer.

DJ-1: a Novel Independent Prognostic Marker for Survival in Glottic Squamous Cell Carcinoma.

Value of the CEA, SCCA, CYFRA21-1, NSE and D-D combined detection in the diagnosis of lung cancer

Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches

Clinical Value of Serum CYFRA 21-1, NSE and CEA in the Diagnosis and Prognosis of Lung Cancer

Cancer-Testis Antigen LDH-C4 in Tissue, Serum, and Serum-Derived Exosomes Serves as a Promising Biomarker in Lung Adenocarcinoma

Expression and diagnostic value of serum free light chain in lung cancer

Value of Serum ADAM8 Level in Diagnosis of Lung Cancer

DNASE1L3 as a Novel Diagnostic and Prognostic Biomarker for Lung Adenocarcinoma Based on Data Mining

Serum ADAM metallopeptidase domain 12 as a promising diagnostic biomarker for breast and liver cancer

The ratio of lymph node eluate/serum cytokeratin 21-1 is a potential predictor of lymph node metastasis in lung adenocarcinoma

Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer.

Value of joint detection of tumor markers to the diagnosis of lung cancer